Aurobindo Pharma share news and announcements
NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap
Last close ₹1,571.70down ₹39.20 (2.43%)BSE ₹1,569.30
Share price at the NSE close on 23 Oct 2026. Previous close ₹1,610.90.
52-week range of traded prices to 23 Oct 2026
₹1,080.10Low, 24 Oct 2025₹1,740.00High, 24 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹90,432 Cr138th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 5 Aug 2026
- 24.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 21 May 2026
- 2.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 5 Aug 2026
- 10.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 5 Aug 2026
- 11.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 21 May 2026
- 0.20
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,50,60251.3% delivered
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Aurobindo Pharma quarterly results
Aug5Wed
The board met on 5 Aug 2026 to consider financial results
Notice filed 27 Jul 2026
To consider and approve the financial results for the period ended Jun 30, 2026 (opens in a new tab)
Aurobindo Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Aurobindo Pharma financials, year by year
Annual reports17
- Annual report, year to Mar 2026 (opens in a new tab)3 Aug 2026
- Annual report, year to Mar 2025 (opens in a new tab)14 Aug 2025
- Annual report, year to Mar 2024 (opens in a new tab)5 Aug 2024
- Annual report, year to Mar 2023 (opens in a new tab)1 Aug 2023, a zip file
- Annual report, year to Mar 2022 (opens in a new tab)9 Jul 2022, a zip file
12 earlier reports
- Annual report, year to Mar 2021 (opens in a new tab)4 Aug 2021, a zip file
- Annual report, year to Mar 2020 (opens in a new tab)4 Aug 2020, a zip file
- Annual report, year to Mar 2019 (opens in a new tab)5 Aug 2019, a zip file
- Annual report, year to Mar 2018 (opens in a new tab)4 Sep 2018, a zip file
- Annual report, year to Mar 2017 (opens in a new tab)4 Sep 2017, a zip file
- Annual report, year to Mar 2016 (opens in a new tab)29 Aug 2016, a zip file
- Annual report, year to Mar 2015 (opens in a new tab)3 Aug 2015, a zip file
- Annual report, year to Mar 2014 (opens in a new tab)1 Aug 2014, a zip file
- Annual report, year to Mar 2013 (opens in a new tab)15 Jul 2013, a zip file
- Annual report, year to Mar 2012 (opens in a new tab)20 Jul 2012, a zip file
- Annual report, year to Mar 2011 (opens in a new tab)11 May 2012, a zip file
- Annual report, year to Mar 2010 (opens in a new tab)8 Sep 2010, a zip file
Investor presentations55
- Investor Presentation (opens in a new tab)5 Aug 2026
- Investor Presentation (opens in a new tab)21 May 2026
- Investor Presentation (opens in a new tab)10 Feb 2026
- Investor Presentation (opens in a new tab)9 Feb 2026
- Investor Presentation (opens in a new tab)5 Nov 2025
50 earlier presentations
- Investor Presentation (opens in a new tab)4 Aug 2025
- Investor Presentation (opens in a new tab)26 May 2025
- Investor Presentation (opens in a new tab)6 Feb 2025
- Investor Presentation (opens in a new tab)10 Aug 2024
- Investor Presentation (opens in a new tab)25 May 2024
- Investor Presentation (opens in a new tab)13 Mar 2024
- Investor Presentation (opens in a new tab)10 Feb 2024
- Investor Presentation (opens in a new tab)9 Nov 2023
- Investor Presentation (opens in a new tab)27 May 2023
- Investor Presentation (opens in a new tab)9 Feb 2023
- Please refer to our letter dated November 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on November 14, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the Second quarter and half year ended September 30, 2022.The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/presentations/ (opens in a new tab)12 Nov 2022
- Further to our letter dated September 6, 2022 informing about the participation in the Kotak Institutional Equity Healthcare Forum 2022 on September 8, 2022, we inform you that the presentation updated in the following weblink of the Company will be used during the interaction with the investors.https://www.aurobindo.com/wp-content/uploads/2022/09/Aurobindo-Pharma_Investor-Presentation_INR_Sep-22.pdfNo unpublished price sensitive information (UPSI) is intended to be discussed during the interactions. (opens in a new tab)7 Sep 2022
- Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first quarter ended June 30, 2022. The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/ (opens in a new tab)11 Aug 2022
- Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022. The presentation is also being uploaded in the following weblink of the Company.https://www.aurobindo.com/investors/results-reports-presentations/results-announcements/ (opens in a new tab)30 May 2022
- Investor Presentation (opens in a new tab)9 Feb 2022
- Investor Presentation (opens in a new tab)8 Nov 2021
- Investor Presentation (opens in a new tab)12 Aug 2021
- Investor Presentation (opens in a new tab)31 May 2021
- Investor Presentation (opens in a new tab)10 Feb 2021
- Investor Presentation (opens in a new tab)11 Nov 2020
- Investor Presentation (opens in a new tab)12 Aug 2020
- Investor Presentation (opens in a new tab)3 Jun 2020
- Investor Presentation (opens in a new tab)6 Feb 2020
- Investor Presentation (opens in a new tab)12 Nov 2019
- Investor Presentation (opens in a new tab)7 Aug 2019
- Investor Presentation (opens in a new tab)28 May 2019
- Investor Presentation (opens in a new tab)7 Feb 2019
- Investor Presentation (opens in a new tab)12 Nov 2018
- Investor Presentation (opens in a new tab)9 Aug 2018, a zip file
- Investor Presentation (opens in a new tab)28 May 2018, a zip file
- Investor Presentation (opens in a new tab)7 Feb 2018, a zip file
- Investor Presentation (opens in a new tab)8 Jan 2018, a zip file
- Investor Presentation (opens in a new tab)16 Nov 2017, a zip file
- Investor Presentation (opens in a new tab)9 Nov 2017, a zip file
- Investor Presentation (opens in a new tab)9 Aug 2017, a zip file
- Investor Presentation (opens in a new tab)26 Jun 2017, a zip file
- Investor Presentation (opens in a new tab)14 Jun 2017, a zip file
- Investor Presentation (opens in a new tab)1 Jun 2017, a zip file
- Investor Presentation (opens in a new tab)29 May 2017, a zip file
- Investor Presentation (opens in a new tab)24 Mar 2017, a zip file
- Investor Presentation (opens in a new tab)22 Feb 2017, a zip file
- Investor Presentation (opens in a new tab)13 Feb 2017, a zip file
- Investor Presentation (opens in a new tab)9 Feb 2017, a zip file
- Investor Presentation (opens in a new tab)9 Jan 2017, a zip file
- Investor Presentation (opens in a new tab)15 Nov 2016, a zip file
- Investor Presentation (opens in a new tab)14 Nov 2016, a zip file
- Presentation to the Investors / Analysts. (opens in a new tab)14 Sep 2016, a zip file
- Presentation to the Investors / Analysts. (opens in a new tab)7 Sep 2016, a zip file
- Presentation to the Investors / Analysts. (opens in a new tab)29 Aug 2016, a zip file
- Investors/Analysts Presentation (opens in a new tab)23 Aug 2016, a zip file
Earnings calls31
- Transcript (opens in a new tab)13 Aug 2026
- Transcript (opens in a new tab)27 May 2026
- Transcript (opens in a new tab)16 Feb 2026
- Transcript (opens in a new tab)11 Nov 2025
- Transcript (opens in a new tab)8 Aug 2025
26 earlier call documents
- Transcript (opens in a new tab)2 Jun 2025
- Transcript (opens in a new tab)13 Feb 2025
- Transcript (opens in a new tab)18 Nov 2024
- Link of Recording (opens in a new tab)11 Nov 2024
- Transcript (opens in a new tab)16 Aug 2024
- Link of Recording (opens in a new tab)12 Aug 2024
- Transcript (opens in a new tab)31 May 2024
- Link of Recording (opens in a new tab)27 May 2024
- Transcript (opens in a new tab)16 Feb 2024
- Link of Recording (opens in a new tab)12 Feb 2024
- Transcript (opens in a new tab)15 Nov 2023
- Link of Recording (opens in a new tab)10 Nov 2023
- Transcript (opens in a new tab)18 Aug 2023
- Link of Recording (opens in a new tab)14 Aug 2023
- Please refer to our letter dated May 19, 2023, wherein we intimated about the schedule of Investors/ Analysts call on May 29, 2023. We are attaching herewith the Transcript of the said analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2023, and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-call-transcripts/ (opens in a new tab)1 Jun 2023
- Link of Recording (opens in a new tab)29 May 2023
- Transcript (opens in a new tab)17 Feb 2023
- And further to our letter dated February 3, 2023, please note that the audio recording of the earnings call on the unaudited financial results for the third quarter and nine months period ended December 31, 2022, held on February 10, 2023, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/ (opens in a new tab)10 Feb 2023
- Sub: Transcript of Q2FY23 earnings call.Please refer to our letter dated November 8, 2022 wherein we intimated about the schedule of Investors/Analysts call on November 14, 2022. We are attaching herewith the Transcript of the said analyst / investorcall on the Unaudited Financial Results of the Company for the second quarter and half year endedSeptember 30, 2022 and the same is being uploaded on the website of the Company and is available in thefollowing web link.https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/conference-calltranscripts/Please take the information on record. (opens in a new tab)18 Nov 2022
- And further to our letter dated November 8, 2022, please note that the audio recording of the earnings call on the unaudited financial results for the second quarter and half year ended September 30, 2022, held on November 14, 2022, at 8.30 AM (IST), has been uploaded on our website on the following web-link:https://www.aurobindo.com/investors/disclosures-under-regulation-46/investor-meet/audio-or-video-recordings/ (opens in a new tab)14 Nov 2022
- Please refer to our letter dated August 8, 2022 wherein we have intimated the schedule of Investors/ Analysts call on August 12, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/ (opens in a new tab)19 Aug 2022
- Please refer to our letter dated May 26, 2022 wherein we have intimated the schedule of Investors/ Analysts call on May 31, 2022. We are attaching herewith the Transcript of the analyst / investor call on the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and the same is being uploaded on the website of the Company and is available in the following web link.https://www.aurobindo.com/investors/results-reports-presentations/conference-call-transcripts/ (opens in a new tab)6 Jun 2022
- And further to our letter dated May 26, 2022, please note that the audio recording of the earnings call for the fourth quarter and financial year ended March 31, 2022, held on May 31, 2022, at 8.30 AM (IST) has been uploaded on our website on the following web-link:https://www.aurobindo.com/wp-content/uploads/2022/05/Aurobindo-Q4-.mp3 (opens in a new tab)31 May 2022
- Transcript (opens in a new tab)17 Feb 2022
- Transcript (opens in a new tab)19 Nov 2021
- Transcript of earnings call. (opens in a new tab)2 Sep 2016, a zip file
Aurobindo Pharma share news and announcements
1,689 announcements, routine notices left out, newest first. Page 1 of 34.
Oct 2026
2 Oct · General Updates
2 Oct · Business
1 Oct · Business
Sep 2026
21 Sep · Analysts
12 Sep · Business
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
11 Sep · Analysts
Aug 2026
25 Aug · Analysts
14 Aug · Analysts
Jul 2026
Jun 2026
25 Jun · Business
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts).
- 6 Aug 2026Resultsdown 1.52%−1.5 pts vs Nifty 500market median −0.7% · five sessions +3.3% (+3.6 pts vs Nifty 500) · volume 1.4× usual · delivery −15.9 pts against usual · The announcement (opens in a new tab)
- 22 May 2026Resultsdown 5.38%−5.6 pts vs Nifty 500market median −0.7% · five sessions −7.8% (−8.0 pts vs Nifty 500) · volume 2.4× usual · delivery −17.2 pts against usual · The announcement (opens in a new tab)
- 22 May 2026Board or managers changeddown 5.38%−5.6 pts vs Nifty 500market median 0.0% · five sessions −7.8% (−8.0 pts vs Nifty 500) · volume 2.4× usual · delivery −17.2 pts against usual · The announcement (opens in a new tab)
- 18 May 2026Buybackdown 0.75%−0.4 pts vs Nifty 500market median 0.0% · five sessions −3.2% (−3.7 pts vs Nifty 500) · volume 0.7× usual · delivery +2.9 pts against usual · The announcement (opens in a new tab)
- 22 Apr 2026Buybackup 2.12%+2.3 pts vs Nifty 500market median 0.0% · five sessions +2.2% (+3.4 pts vs Nifty 500) · volume 1.0× usual · delivery +4.0 pts against usual · The announcement (opens in a new tab)
- 6 Nov 2025Resultsdown 0.74%−0.1 pts vs Nifty 500market median −0.7% · five sessions +3.0% (+2.3 pts vs Nifty 500) · volume 1.0× usual · delivery −19.7 pts against usual · The announcement (opens in a new tab)
- 4 Nov 2025Board or managers changeddown 0.82%−0.3 pts vs Nifty 500market median 0.0% · five sessions +0.8% (+1.4 pts vs Nifty 500) · volume 0.7× usual · delivery −3.4 pts against usual · The announcement (opens in a new tab)
- 1 Oct 2025Board or managers changedup 0.19%−0.7 pts vs Nifty 500market median 0.0% · five sessions −1.2% (−2.9 pts vs Nifty 500) · volume 0.7× usual · delivery +10.2 pts against usual · The announcement (opens in a new tab)
- 5 Aug 2025Resultsdown 1.02%−0.7 pts vs Nifty 500market median −0.7% · five sessions −3.4% (−2.4 pts vs Nifty 500) · volume 2.4× usual · delivery −8.5 pts against usual · The announcement (opens in a new tab)
- 5 Aug 2025Dividenddown 1.02%−0.7 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−2.4 pts vs Nifty 500) · volume 2.4× usual · delivery −8.5 pts against usual · The announcement (opens in a new tab)
20 earlier announcements
- 7 Feb 2025Resultsdown 0.01%+0.1 pts vs Nifty 500market median −0.7% · five sessions −1.0% (+2.5 pts vs Nifty 500) · volume 1.4× usual · delivery −17.6 pts against usual · The announcement (opens in a new tab)
- 16 Dec 2024Board or managers changedup 3.00%+3.0 pts vs Nifty 500market median 0.0% · five sessions +2.8% (+7.2 pts vs Nifty 500) · volume 1.1× usual · delivery −7.8 pts against usual · The announcement (opens in a new tab)
- 11 Nov 2024Resultsdown 2.90%−2.7 pts vs Nifty 500market median −0.7% · five sessions −6.9% (−3.6 pts vs Nifty 500) · volume 4.1× usual · delivery −13.1 pts against usual · The announcement (opens in a new tab)
- 26 Aug 2024Buybackup 0.63%0.0 pts vs Nifty 500market median 0.0% · five sessions +2.0% (+0.7 pts vs Nifty 500) · volume 0.4× usual · delivery −25.9 pts against usual · The announcement (opens in a new tab)
- 12 Aug 2024Resultsup 0.83%+0.9 pts vs Nifty 500market median −0.7% · five sessions +4.8% (+3.9 pts vs Nifty 500) · volume 1.6× usual · delivery −5.1 pts against usual · The announcement (opens in a new tab)
- 27 May 2024Resultsdown 3.13%−3.2 pts vs Nifty 500market median −0.7% · five sessions −4.0% (−2.2 pts vs Nifty 500) · volume 2.9× usual · delivery −20.9 pts against usual · The announcement (opens in a new tab)
- 8 Apr 2024Board or managers changeddown 0.31%−0.8 pts vs Nifty 500market median 0.0% · five sessions −3.4% (−2.3 pts vs Nifty 500) · volume 1.1× usual · delivery −2.9 pts against usual · The announcement (opens in a new tab)
- 6 Mar 2024Board or managers changeddown 2.18%−2.2 pts vs Nifty 500market median 0.0% · five sessions −7.2% (−3.6 pts vs Nifty 500) · volume 0.6× usual · delivery −3.5 pts against usual · The announcement (opens in a new tab)
- 12 Feb 2024Dividendup 1.55%+3.0 pts vs Nifty 500market median 0.0% · five sessions +3.1% (+2.1 pts vs Nifty 500) · volume 2.1× usual · delivery −18.7 pts against usual · The announcement (opens in a new tab)
- 12 Feb 2024Board or managers changedup 1.55%+3.0 pts vs Nifty 500market median 0.0% · five sessions +3.1% (+2.1 pts vs Nifty 500) · volume 2.1× usual · delivery −18.7 pts against usual · The announcement (opens in a new tab)
- 7 Feb 2024Dividenddown 1.99%−2.4 pts vs Nifty 500market median 0.0% · five sessions +1.2% (+2.4 pts vs Nifty 500) · volume 2.0× usual · delivery +6.1 pts against usual · The announcement (opens in a new tab)
- 10 Nov 2023Dividendup 3.05%+2.8 pts vs Nifty 500market median 0.0% · five sessions +2.7% (+0.5 pts vs Nifty 500) · volume 3.0× usual · delivery −27.3 pts against usual · The announcement (opens in a new tab)
- 29 May 2023Resultsdown 0.58%−1.1 pts vs Nifty 500market median −0.7% · five sessions +7.7% (+7.0 pts vs Nifty 500) · volume 3.1× usual · delivery −16.4 pts against usual · The announcement (opens in a new tab)
- 10 Feb 2023Dividendup 6.33%+6.4 pts vs Nifty 500market median 0.0% · five sessions +8.8% (+8.5 pts vs Nifty 500) · volume 6.3× usual · delivery −28.7 pts against usual · The announcement (opens in a new tab)
- 14 Nov 2022Resultsdown 0.38%−0.4 pts vs Nifty 500market median −0.7% · five sessions −4.1% (−3.5 pts vs Nifty 500) · volume 4.6× usual · delivery −27.0 pts against usual · The announcement (opens in a new tab)
- 31 May 2022Dividendup 0.50%+0.8 pts vs Nifty 500market median 0.0% · five sessions −1.1% (−0.4 pts vs Nifty 500) · volume 3.3× usual · delivery +13.3 pts against usual · The announcement (opens in a new tab)
- 10 Feb 2022Dividendup 4.32%+3.7 pts vs Nifty 500market median 0.0% · five sessions +5.2% (+6.7 pts vs Nifty 500) · volume 3.8× usual · delivery −11.3 pts against usual · The announcement (opens in a new tab)
- 9 Nov 2021Dividendup 0.74%+0.6 pts vs Nifty 500market median 0.0% · five sessions +3.5% (+3.1 pts vs Nifty 500) · volume 5.7× usual · delivery −21.6 pts against usual · The announcement (opens in a new tab)
- 4 Oct 2021Board or managers changedup 2.07%+1.0 pts vs Nifty 500market median 0.0% · five sessions −0.4% (−2.7 pts vs Nifty 500) · volume 2.4× usual · delivery −11.8 pts against usual · The announcement (opens in a new tab)
- 13 Aug 2021Resultsdown 7.86%−8.5 pts vs Nifty 500market median −0.7% · five sessions −17.6% (−17.4 pts vs Nifty 500) · volume 13.4× usual · delivery −12.1 pts against usual · The announcement (opens in a new tab)
Aurobindo Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.